Vibrent Health partners with Fred Hutchinson Cancer Center to Validate a Landmark BARDA-funded Large-Scale Hybrid/Remote Approach for NextGen Clinical Research

Bringing Infectious Disease Research to People Where They Live and Play

FAIRFAX, Va.–12 Feb., 2025–Vibrent Health, a leading software-as-a-service SaaS data company in the field of precision medicine research, announced today its collaboration with the Fred Hutch Cancer Center (FHCC) under a $17 million contract awarded through the Biomedical Advanced Research and Development Authority’s (BARDA) Rapid Response Partnership Vehicle (RRPV) Consortium. This partnership will drive critical research on correlates of protection (CoPs) through decentralized clinical trials (DCTs) as part of the federal government’s Project NextGen initiative.

Project NextGen, a $5 billion program led by BARDA and the National Institute of Allergy and Infectious Diseases (NIAID), aims to accelerate the development of next-generation vaccines, therapeutics, and supporting technologies. Central to this effort is the identification and validation of CoPs, which are measurable indicators of immunity against disease.

“This research represents a pivotal step in understanding how the immune system responds to vaccines through the use of real-world data collected remotely,” said Praduman “PJ” Jain, CEO, Vibrent Health. “By identifying correlates of protection in large population, we can drive innovation to improve public health preparedness for future infectious disease outbreaks.”

Traditional clinical trials often require participants to travel to research sites, creating barriers to enrollment and limiting diversity.Vibrent Health, in partnership with Fred Hutchinson, BARDA and others, is transforming this model by bringing clinical research directly to people where they live.  Through patient-centric digital engagement, remote biospecimen collection, and seamless real-world data integration, this approach expands access and accelerates scientific discovery.

“This BARDA study expands access, enhances data quality, and accelerates the development of next-generation therapeutics and treatments,” said Peter Gilbert, Principal Investigator, Fred Hutch Cancer Center. “By identifying and validating correlates of protection, this research not only informs the development of more targeted and effective treatments for infectious diseases but also establishes a framework that can be applied to a wide range of clinical trials, improving outcomes and speeding up the path to approval.”

By reducing the burden on participants and increasing representation, this next-generation model makes clinical trials more scalable, and efficient. Vibrent’s role in this BARDA-funded study demonstrates how decentralized and hybrid trials are shaping the future of infectious disease research—where participation is easier, real-world data is richer, and public health advancements happen faster.

“Advancing clinical research requires a broad approach that allows for remotely collected real-world data while streamlining clinical operations to enhance efficiency and accelerate research outcomes.” said Jessica Andriesen, Director of Operations, Statistical and Data Coordinating Center, Fred Hutch Cancer Center. “Vibrent Health’s technology makes these advances possible in an integrated way this is operationally efficient and leads to high quality results”.

Vibrent’s underlying research data management platform centralizes complex datasets to enhance transparency for site staff and researchers. This centralized data model ensures the availability of high-quality, reproducible data critical for drawing meaningful scientific conclusions, combining electronic patient-reported outcomes (ePROs), electronic case report forms (eCRFs), biospecimen data, and operational metrics.  Vibrent also spearheaded the delivery of advanced dashboards offering real-time insights into trial metrics, such as participant enrollment, diversity representation, and adverse event monitoring.  Dynamic visualizations allow for site-specific data analysis and tracking for the study team.

The same scalable model used in this BARDA-funded study can be used in commercial studies across multiple therapeutic areas such as oncology, precision medicine, metabolic, neuroscience and others, making Vibrent a trusted technology partner.  Vibrent Health’s platform is available for biopharma sponsors, CROs, and research organizations seeking scalable, highly integrated solutions for decentralized and hybrid trials.

To learn more or discuss a potential research collaboration, visit: https://info.vibrenthealth.com/request-a-pilot.